BioCentury
ARTICLE | Finance

Ebb & Flow

January 31, 2005 8:00 AM UTC

Alta Partners thinks that the recent sale of its portfolio company Angiosyn to Pfizer (PFE) represents the realist's approach to managing the risk of early stage, one-horse companies. The specific terms of PFE's acquisition of the angiogenesis company weren't disclosed, but could total $527 million if Angiosyn's lone preclinical compound is commercialized in two areas, including age-related macular degeneration.

Angiosyn's compound has its roots in the lab of Paul Schimmel, a professor of molecular biology at the Scripps Research Institute. He and Alta formed Angiosyn in May 2003. ...